Vortioxetina nel trattamento della depressione maggiore

Dec 21, 2016Rivista di psichiatria

Vortioxetine for treating major depression

AI simplified

Psychedelic Science on OpenScience ↗PubMed ↗DOI ↗

Abstract

A meta-analysis of 11 studies shows vortioxetine 5-20 mg/day effectively treats major depressive disorder symptoms.

Efficacy increases with higher doses of vortioxetine.
Improvement was observed across all individual depression symptoms measured by the MADRS scale.
Vortioxetine is effective for severe depression and cases with inadequate response to previous SSRI or SNRI treatments.
The medication may help prevent relapse in patients with major depressive disorder.
Cognitive performance in patients with acute major depressive disorder may improve with vortioxetine.
Vortioxetine is generally well-tolerated, with limited effects on weight gain and sexual functioning.

AI simplified

Notwithstanding the high prevalence, functional burden, negative consequences and risk of chronicity of major depressive disorder, few innovative medications have been developed in recent years for the treatment of this heterogeneous disease. Vortioxetine is a multi-modal antidepressant that functions both as serotonin transporter (SERT) inhibitor and as 5-HT3, 5-HT7 and 5-HT1D receptors antagonist, 5-HT1A receptor agonist and 5-HT1B receptor partial agonist. A recent meta-analysis of 11 randomized, double-blind, placebo controlled, acute (6-8 weeks) treatment studies has demonstrated the efficacy of vortioxetine 5-20 mg/day in the treatment of depression, with an increasing effect associated with increasing dose. Additionally, vortioxetine 5-20 mg/day has shown efficacy on the whole range of depression symptoms (as demonstrated by the improvement of all single-item MADRS scores). Vortioxetine has also been shown effective in the treatment of severe depression and depression with inadequate response to a previous SSRI or SNRI treatment, as well as in the prevention of relapse. In studies designed to assess cognition in depression, vortioxetine showed evidence of improving cognitive performance in patients with acute major depressive disorder. Vortioxetine appears well-tolerated, with very limited effects on weight gain and sexual functioning. The most commonly occurring adverse event (nausea) was generally transitory.

Vortioxetina nel trattamento della depressione maggiore

Abstract

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief

Abstract

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief